News
14 January 2015
ESMO-led Anti-Cancer Medicines Availability Study
The peer review deadline has just been extended as ESMO are missing reviews for some important countries.

Your assistance would be appreciated on three actions:
- Review the data online - select the tumour types you wish to review
- Leave any comments online or mail them to Nathan Cherny
- Please forward this study to colleagues for their review
This far-reaching study will have an important impact on the current medical landscape and aims to have long-term, hard-hitting consequences on medicine accessibility for patients across Europe.
Useful info
Please paste this url into your browser should you encounter problems
https://eu.qualtrics.com/SE/?SID=SV_8xdgeNHUhBJ4yuF
Please visit this page for helpful tips on reviewing data
Tags
ESMO
Last update
Friday 07 June 2019